|
Market Closed -
Nasdaq
16:00:00 2026-08-13 EDT
|
5-day change | 1st Jan Change | ||
| 6.100 USD | +0.83% |
|
+9.91% | -47.64% |
| 08-13 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-13 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
Company Valuation: ARS Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 799.9 | 526.1 | 1,025 | 1,152 | 605.7 | - | - |
| Change | - | -34.23% | 94.9% | 12.32% | -47.4% | - | - |
| Enterprise Value (EV) | 525.5 | 297.7 | 1,025 | 1,152 | 605.7 | 605.7 | 605.7 |
| Change | - | -43.35% | 244.4% | 12.32% | -47.4% | 0% | 0% |
| P/E | -9.8x | -9.61x | 132x | -6.7x | -3.52x | -7.11x | 131x |
| PBR | - | - | - | - | - | - | - |
| PEG | -2.03x | 0.3x | -1x | 0x | 12.25x | 0.1x | -1x |
| Capitalization / Revenue | 608x | 17,535x | 11.5x | 13.7x | 4.48x | 2.67x | 1.69x |
| EV / Revenue | 0x | 0.01x | 0x | 0x | 4.48x | 2.67x | 1.69x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -3.26x | -7.08x | -711x |
| EV / FCF | - | - | 0x | -0x | -3.15x | -7.64x | 11.6x |
| FCF Yield | - | - | 1.27% | -14.9% | -31.7% | -13.1% | 8.62% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.87 | -0.57 | 0.08 | -1.74 | -1.735 | -0.8575 | 0.0467 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 1.316 | 0.03 | 89.15 | 84.28 | 135.4 | 227.1 | 359.3 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -35.52 | -67.52 | -3.083 | -179.4 | -185.9 | -85.57 | -0.852 |
| Net income 1 | -34.68 | -54.36 | 7.998 | -171.3 | -188.8 | -90.33 | -2.1 |
| Net Debt | -274.4 | -228.4 | - | - | - | - | - |
| Reference price 2 | 8.530 | 5.480 | 10.550 | 11.650 | 6.100 | 6.100 | 6.100 |
| Nbr of stocks (in thousands) | 93,770 | 95,997 | 97,185 | 98,849 | 99,303 | - | - |
| Announcement Date | 3/23/23 | 3/21/24 | 3/20/25 | 3/9/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.52x | - | - | - | 606M | |
| 33.64x | 6.01x | 17.86x | 0.95% | 49.24B | |
| -20.97x | 286.12x | -21.24x | -.--% | 43.3B | |
| 46.63x | 5.39x | 29.47x | -.--% | 40.48B | |
| 31.1x | 3.08x | 13.28x | -.--% | 39.75B | |
| 30.74x | 8.86x | 22.27x | 0.38% | 32.67B | |
| 33.09x | 5.41x | 24.6x | -.--% | 16.24B | |
| 23.37x | 2.05x | 8.85x | 1.15% | 14.04B | |
| 75.26x | 3.97x | 15.41x | -.--% | 13.43B | |
| Average | 27.71x | 40.11x | 13.81x | 0.31% | 27.75B | |
| Weighted average by Cap. | 27.03x | 54.12x | 12.60x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRY Stock
- Valuation ARS Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
